Semi-Annual Report — FY2026 H1
What D.Western Therapeutics Institute, Inc. reported for the period from 2026-01-01 to 2026-12-31. Filed by 株式会社デ・ウエスタン・セラピテクス研究所
Filed 2026-08-13View the original on EDINET
How much it says
50Typical
What moved here
22named for the first time
Its own wording
35terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim consolidated accounting period, the group recorded net sales of ¥33 million, mainly from sales of the Gralfa® combination ophthalmic solution, while continuing to report an operating loss. For the glaucoma treatment H-1337, the group concluded an option agreement covering Japan, Asia and other regions with 千寿製薬. For Bondlido (DW-5LBT), the group also reported agreement on the basic terms of a U.S. distribution partnership.
Komori's summary of this document, not the document's own words.50Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
48
Typical
38
Thin
0
Almost nothing
0
Almost nothing
55
Typical
100
Very detailed
53
Typical
55
Typical
50
Typical
R&D spend2億円Money spent making new things.
Cash left over-8億円Cash from the business, less what went into equipment.
Spent on equipment-3百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.